Valuation: Virbac

Market Cap 2.79B 3.23B 2.62B 2.38B 4.48B 308B 4.55B 30.67B 11.99B 154B 12.11B 11.85B 513B P/E 2026 *
16.3x
P/E 2027 * 14.8x
Enterprise Value 2.91B 3.37B 2.74B 2.49B 4.68B 322B 4.76B 32.07B 12.54B 161B 12.66B 12.39B 537B EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.74x
Free-Float
49.03%
Yield 2026 *
0.52%
Yield 2027 * 0.61%
1 day-6.07%
1 month-6.07%
3 months-6.07%
6 months-12.16%
Current year-12.16%
1 month 382.75
Extreme 382.75
435.44
Current year 382.75
Extreme 382.75
435.44
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 31/08/2025
Chief Executive Officer 50 26/09/2024
Chief Operating Officer 64 31/12/2021
Director TitleAgeSince
Chairman 61 31/03/2006
Director/Board Member 68 27/07/2010
Director/Board Member 65 04/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+27.70%-.--% - - 3.23B
-2.70%+1.56%-52.12%-60.39% 30.49B
+5.15%+7.01%+31.79%+105.11% 11.83B
-0.48%-2.25%-20.12%+2.48% 3.77B
+0.30%-3.62%+0.45%+18.33% 3.23B
-0.81%-2.38%+51.51%+38.77% 2.19B
-0.28%+0.71%+13.74%+30.93% 1.97B
+0.88%+0.20%+12.03%+127.25% 1.39B
-2.18%+5.77%-15.50%+6.18% 1.3B
-0.90%+0.30%-12.73%-43.76% 996M
Average -0.71%+0.36%+1.01%+24.99% 6.35B
Weighted average by Cap. -0.77%+1.85%-20.37%-4.24%

Financials

2026 *2027 *
Net sales 1.55B 1.8B 1.46B 1.33B 2.49B 172B 2.53B 17.08B 6.68B 85.99B 6.74B 6.6B 286B 1.65B 1.91B 1.55B 1.41B 2.65B 182B 2.69B 18.14B 7.09B 91.33B 7.16B 7.01B 303B
Net income 171M 198M 161M 146M 275M 18.94B 279M 1.88B 737M 9.49B 744M 728M 31.53B 190M 219M 178M 162M 305M 20.99B 310M 2.09B 816M 10.51B 824M 806M 34.92B
Net Debt 127M 147M 119M 108M 204M 14.03B 207M 1.4B 546M 7.03B 551M 539M 23.35B 75.16M 87.02M 70.63M 64.23M 121M 8.32B 123M 828M 324M 4.17B 327M 320M 13.85B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
332.50EUR
Average target price
411.88EUR
Spread / Average Target
+23.87%

Quarterly revenue - Rate of surprise